NASDAQ:BJDX Bluejay Diagnostics (BJDX) Stock Price, News & Analysis $2.60 -0.01 (-0.38%) As of 09:53 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Bluejay Diagnostics Stock (NASDAQ:BJDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bluejay Diagnostics alerts:Sign Up Key Stats Today's Range$2.68▼$2.6850-Day Range$2.12▼$4.1252-Week Range$1.84▼$28.00Volume293 shsAverage Volume536,068 shsMarket Capitalization$2.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer. Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations. Bluejay Diagnostics is headquartered in Acton, Massachusetts, and serves the healthcare market through the development of diagnostic products for hospitals, clinics and other point-of-care environments. The company’s strategy centers on advancing and commercializing its Symphony technology and related assays.AI Generated. May Contain Errors. Read More Bluejay Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreBJDX MarketRank™: 0.891102257635 of 5 starsBluejay Diagnostics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBluejay Diagnostics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBluejay Diagnostics has only been the subject of 1 research reports in the past 90 days.Read more about Bluejay Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bluejay Diagnostics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bluejay Diagnostics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBluejay Diagnostics has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.43% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 1.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently decreased by 46.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBluejay Diagnostics does not currently pay a dividend.Dividend GrowthBluejay Diagnostics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.16 News SentimentBluejay Diagnostics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bluejay Diagnostics this week, compared to 2 articles on an average week. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders6.10% of the stock of Bluejay Diagnostics is held by insiders.Percentage Held by Institutions18.47% of the stock of Bluejay Diagnostics is held by institutions.Read more about Bluejay Diagnostics' insider trading history. Receive BJDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BJDX Stock News HeadlinesBluejay Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13 at 9:48 AM | marketscreener.comMBluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12, 2026 | finance.yahoo.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 16 at 1:00 AM | Behind the Markets (Ad)Bluejay Diagnostics (BJDX) Expected to Release Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comBluejay Diagnostics, Inc. Completes Establishment of Manufacturing Site for Symphonytm CartridgesOctober 14, 2026 | marketscreener.comM5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & AtaraSeptember 8, 2026 | rttnews.comBluejay Diagnostics federal healthcare partnership builds commercial pathway ahead of FDA clearanceSeptember 8, 2026 | msn.comBluejay Diagnostics, Lovell Team Up To Access U.S. Federal Healthcare MarketSeptember 8, 2026 | rttnews.comSee More Headlines BJDX Stock Analysis - Frequently Asked Questions How have BJDX shares performed this year? Bluejay Diagnostics' stock was trading at $10.6752 on January 1st, 2026. Since then, BJDX stock has decreased by 75.6% and is now trading at $2.61. How were Bluejay Diagnostics' earnings last quarter? Bluejay Diagnostics, Inc. (NASDAQ:BJDX) posted its quarterly earnings data on Thursday, November, 12th. The company reported ($1.72) earnings per share for the quarter, beating analysts' consensus estimates of ($3,520.00) by $3,518.28. When did Bluejay Diagnostics' stock split? Bluejay Diagnostics shares reverse split before market open on Thursday, June 20th 2024.The 1-8 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Bluejay Diagnostics IPO? Bluejay Diagnostics (BJDX) raised $0 in an initial public offering on Tuesday, November 9th 2021. The company issued 2,160,000 shares at $0.00 per share. How do I buy shares of Bluejay Diagnostics? Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bluejay Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bluejay Diagnostics investors own include Pasithea Therapeutics (KTTA), Archer Aviation (ACHR), AMC Entertainment (AMC), Azitra (AZTR), Aeva Technologies (AEVA), Amarin (AMRN) and Auddia (AUUD). Company Calendar Last Earnings11/12/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BJDX's financial health is in the Yellow zone, according to TradeSmith. BJDX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BJDX CIK1704287 Webwww.bluejaydx.com Phone844-327-7078FaxN/AEmployees6Year Founded2015Profitability EPS (Trailing Twelve Months)($28.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-113.79% Return on Assets-91.42% Debt Debt-to-Equity RatioN/A Current Ratio3.91 Quick Ratio3.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$33.73 per share Price / Book0.08Miscellaneous Outstanding Shares1,117,000Free Float1,049,000Market Cap$2.92 million OptionableNot Optionable Beta0.92 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BJDX) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.